L granulomatosis are related angiocentric, angiodestructive lymphoproliferative disorders that involve the upper and lower respiratory tracts, respectively. They are both characterized by a heterogeneous infiltrate composed of small lymphocytes, mononuclear phagocytes, plasma cells, occasional eosinophils, and variable numbers of large, atypical lymphoid cells, not unlike the reactive infiltrate observed in Hodgkin's disease. Because of the lack of a predominant, clearly malignant population identifiable on histopathologic examination, these two clinicopathologic entities were assigned to a pathologic purgatory of descriptive diagnostic designations instead of classification as a non-Hodgkin's lymphoma, despite a malignant clinical course in the absence of therapy.
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A historical perspective shows that current technologies have provided profound molecular insights into the nature of this spectrum of lymphoproliferative disorders, although many questions remain. The report by Borisch et all in this issue of Blood demonstrates that a subtype of Epstein-Barr virus (EBV) commonly isolated from immunocompromised individuals is frequently associated with midline granuloma.
Typically, reports of lethal midline granuloma describe a prodromal phase with nasal symptoms of months to years duration, followed by the onset of ulcers that efface midline nasopharyngeal structures, resulting in fatal complications related to cachexia, hemorrhage, or infection. Originally, Edgerton and DesPrez2 questioned the nature of lethal midline granuloma: "It is still an unsolved question whether lethal midline granuloma represents a tumour unlike all other tumours, an infection unlike other infections, or a defect in the immune mechanism." Similarly, Liebow et a13 speculated that there would be controversy as to whether or not lymphomatoid granulomatosis should be classified as a malignant lymphoma. Subsequently, a critical review of nasal lymphoproliferative lesions seen at the Mayo Clinic4 resolved a group constituting approximately 27% of cases, which were composed of a heterogeneous infiltrate that included varying numbers of atypical lymphoid cells associated with necrosis and invasion of blood vessels, as well as chronic changes such as fibrosis, epithelial metaplasia, and hyperplasia, and glandular atrophy, perhaps sequelae of a chronic infection. This group, designated polymorphic reticulosis, had a favorable prognosis and a mean symptomatic interval that was tenfold longer (55 months v 5 months) than was observed in patients with histopathologically proved lymphomas. These lesions were presumed to represent the histologic manifestation of lethal midline granuloma. Although less conspicuous, blood vessel invasion and thrombosis were also observed in 62% of obvious lymphomas, raising the possibility that these lesions evolve into a spectrum, in which highgrade histopathologic features are associated with an aggressive clinical course.
Diagnostic criteria were established to separate lymphomatoid granulomatosis into three categories based on the content of atypical lymphoid c e k 5 pure, focal lymphoma, and diffuse lymphoma. Moreover, both nasal and pulmonary lesions were shown to progress from low-grade to highgrade histopathology over time. Both lethal midline granuloma and lymphomatoid granulomatosis may extend to involve tissues outside the respiratory tract, including lymph nodes, skin, and the central nervous system.
In this context, the term angiocentric immunoproliferative lesion (AIL) was proposed to include both lethal midline granuloma/polymorphic reticulosis and lymphomatoid granulomatosis6 and guidelines for grading were set forth (grade I: polymorphic infiltrate with minimal necrosis, few large atypical lymphoid cells, and small lymphocytes lacking nuclear irregularities; grade 11: cytologic atypia of small lymphocytes, scattered large atypical lymphoid cells, and intermediate amounts of necrosis; and grade 111: lymphoma, either diffuse mixed, large cell, or immunoblastic, with prominent necrosis). Immunologic characterization of AIL shows that the large atypical cells consistently express CD2, frequently CD3 and HLA-DR antigens, and variably CD4, CD5, CD7, and CD25, but not B-lineage differentiation antigen^.'"^ Based on a morphologic resemblance to polymorphic peripheral T-cell lymphomas and the expression of T-lineage antigens (with an immunophenotype that reflects either activation or an unscheduled repertoire), AIL has frequently been considered to be a T-cell lymphoma. Unexpectedly, however, the majority of cases tested express cell surface antigens associated with natural killer (NK) cell differentiation (CD16IFcyRII1, CD56/N-CAM, and/or CD57),8313,14 a rare finding in T-cell lymphomas. Rare cases have been shown to express the lymphocyte activation antigen CD30,14 also a feature of large cell anaplastic lymphomas, which may have either B-or T-lineage differentiation and occur in the nasopharynx.
Surprisingly, molecular biologic analysis of cases of AIL for clonal rearrangements of genes encoding immune receptors, as would be predicted in a non-Hodgkin's lymphoma, Immunocytochemical analysis of expression of TcR polypeptidesL4 confirmed the lack of (productive) aB rearrangements in seven cases, but suggested that there was expression of chains encoded by productive rearrangements of y 6TcR genes in two of them. Genes encoding Ig heavy chains and light chains have been universally reported to be in the germline configuration.
Despite this, both clinical and histopathologic features of AIL point to its being a malignant lymphoma. Alternative interpretations to reconcile the immunophenotypic and genotypic findings include the possibilities that AIL is a T-cell lymphoma derived from a primitive cell type that has not yet undergone activation ofthe recombinase system for rearrangement of TcR genes or that it is derived from NK cells, which do not rearrange these genesL8 However, the infiltrate in AIL lacks cells that express CD antigens associated with early T-lineage differentiation, and the expression of cell surface CD3 molecules in the absence of T-cell receptor molecules, an apparent molecular heresy, is unexplained. On the other hand, expression of CD3 and/or CD4, albeit variable in AIL, is not characteristic of NK cells.
In the original description of lymphomatoid granuloma- Together, these findings provide the first direct evidence that AIL is a clonal process and implicates EBV as a "smoking gun" in the pathogenesis of this disorder. Recognized targets for EBV infection include B lymphocytes and epithelial cells of the nasopharynx.28 However, it also has been shown that human thymocytes and subsets of blood T lymphocytes express the cell surface receptor for EBV (CD2 1)29*30 and can be infected by EBV.3L Because AIL cells have not been found to bind CD2 1 antibodies it is presumed that an alternative receptor is used or that CD2 1 is temporally expressed at the time of infection.
Further evidence for the involvement of EBV as an etiologic agent is derived from the demonstration that lethal midline granulomas express mRNA transcripts encoding the latent membrane protein (LMPI) encoded by EBV,12 as well as the polypeptide it~e1f.l~ Transfection of a cDNA encoding LMPl into rodent fibroblasts results in morphologic transformation, anchorage-independent growth, and tumorigenicity in immunocompromised mice.32 When similarly expressed in B-lymphoblastoid cells, LMP 1 enhances cytoadhesion through induction of expression of adhesion molecules such as LFA-1, LFA-3, and ICAM-1.33 Analogous effects on cognate molecules in the cellular target in AIL could augment cytoadhesion to extracellular matrix proteins resulting in the angiocentricity that is observed in this disorder. LMPl expression protects B cells from programmed cell death through induction of bcl-2 expre~sion,~~ which should be explored in AIL. Finally, an EBV-encoded polypeptide highly homologous to interleukin-10 has been shown to be secreted by infected B cells,35 which could contribute to the heterogeneous inflammatory infiltrate in the background.
Two common biotypes of EBV have been characterized. In addition to the common type (designated A), a second type (designated B) has been described that differs genetically in the sequences encoding EBNA-2, EBNA-3, and small-RNAs (EBER), geographically in its concentration in equatorial Africa, and biologically in its attenuated transforming ability. Sculley et found a higher incidence of antibodies to type B EBNA-2 in human immunodeficiency For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
